Airway Smooth Muscle Inflammation Is Regulated by MicroRNA-145 in COPD

Lawrence O’Leary BSc¹, Kenan Sevinç BSc¹, Ilektra M Papazoglou MSc¹, Bernadett Tildy BSc¹, Karen Detillieux PhD², Andrew J. Halayko PhD², Kian Fan Chung MD¹ and Mark M Perry PhD³

¹Airways Disease, National Heart and Lung Institute, Imperial College, London & Royal Brompton NIHR Biomedical Research Unit, London SW3 6LY, United Kingdom.
²Departments of Internal Medicine & Physiology, Respiratory Hospital, Sherbrook Street, Winnipeg Manitoba, R3A 1R9 Canada.
³Molecular Neurosciences, The Dubowitz Neuromuscular Centre, UCL Institute of Child Health, 30 Guildford Street, London, WC1N 1EH, United Kingdom.

*Corresponding Author:
Dr Mark M Perry
Molecular Neurosciences
The Dubowitz Neuromuscular Centre
UCL Institute of Child Health
30 Guildford Street
London
WC1N 1EH
Tel: 0207 905 2136
Email: mark.perry@ucl.ac.uk
Funding bodies

This work was supported by a fellowship from Imperial College to MMP and a grant from The Wellcome Trust (085935) to KFC. It was also supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton NHS Foundation Trust and Imperial College London. KFC is a Senior Investigator of NIHR, UK. MMP and KFC are members of Interuniversity Attraction Poles Program-Belgian State-Belgian Science Policy-project P7/30.
Abstract

Chronic obstructive pulmonary disease (COPD) is a common, highly debilitating disease of the airways, primarily caused by smoking. Chronic inflammation and structural remodelling are key pathological features of this disease, in part caused by the aberrant function of airway smooth muscle (ASM) cells under the regulation of transforming growth factor (TGF)-β.

MicroRNAs are short, non-coding gene transcripts involved in the negative regulation of specific target genes, through their interactions with messenger RNAs. Previous studies have proposed that microRNA-145 (miR-145) may interact with SMAD3, an important downstream signalling molecule of the TGF-β pathway. TGF-β was used to stimulate primary human ASM cells isolated from healthy non-smokers, healthy smokers and COPD patients. This resulted in a TGF-β-dependent increase in CXCL8 and IL-6 release, most notably in the cells from COPD patients. TGF-β stimulation increased SMAD3 expression, only in cells from COPD patients, with a concurrent increased miR-145 expression.

Regulation of miR-145 was found to be negatively controlled by pathways involving the MAP kinases, MEK-1/2 and p38 MAPK. Subsequent, overexpression of miR-145 (using synthetic mimics) in ASM cells from patients with COPD suppressed IL-6 and CXCL8 release, to levels comparable to the non-smoker controls. Therefore, this study suggests that miR-145 negatively regulates pro-inflammatory cytokine release from ASM cells in COPD by targeting SMAD3.
**Introduction**

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory condition of the lung of high global prevalence and is associated with high morbidity, mortality and socioeconomic cost; moreover, its contribution to deaths worldwide is predicted to increase over the course of both the current and next decade.

COPD is a heterogeneous condition, primarily affecting the lung, but often with significant systemic features, which can augment the morbidity of the disorder and hamper its management. The pulmonary component of the disease refers to a progressive and largely irreversible obstruction of airflow, due to a pathological combination of narrowing of the small airways, parenchymal destruction and structural remodelling. The aberrant remodelling occurs in addition, or in response, to the ongoing and worsening inflammation. It is associated with architectural alterations to the bronchi, small airways and parenchymal tissue and affects the epithelium, its underlying extracellular matrix and the surrounding smooth muscle and these changes have been correlated to disease severity. Though the primary cause of COPD in more economically developed countries is cigarette smoking, the majority of heavy smokers do not develop the disease and indicators for determining those that will be affected remain elusive.

An increased ASM mass has been observed in both the large and small airways in COPD, which correlates with disease severity. Whether increased ASM mass in COPD is due to either hypertrophy or hyperproliferation, or a combination of both has not been definitively determined. ASM cells have also been shown to produce a number of cytokines, chemokines and growth factors in response to a variety of inflammatory stimuli, which may contribute towards the inflammatory process in COPD. Among these secreted cytokines are CXC chemokine ligand 8 (CXCL8) and interleukin 6 (IL-6) both of which have been found to be elevated in the sputum of patients with COPD; even more so during exacerbations.
Transforming growth factor (TGF)-β is a pleiotropic cytokine that stimulates ASM proliferation and pro-inflammatory cytokine production\textsuperscript{11,12}, and elevated TGF-β secretion by pulmonary epithelial cells from patients with COPD has been observed in comparison to healthy controls\textsuperscript{13}. TGF-β signalling is typically through the Smad-dependent pathway\textsuperscript{14} although other signalling pathways can also be involved, including the nuclear factor-κB (NF-κB) pathway, pathways involving mitogen-activated protein kinases (MAPKs) and the Wingless/integrase-1 (WNT) pathway\textsuperscript{15}.

In addition to the transcription of messenger RNAs (mRNAs), which forms the first step of the “central dogma of molecular biology”, non-coding RNAs are transcribed from DNA\textsuperscript{16}. miRNAs bind, in a complementary manner, to the 3` end of their target mRNAs and instigate there suppression/degradation\textsuperscript{16}. Cell proliferation has been shown to be regulated by microRNA-221 (\textit{miR}-221) in ASM cells from patients with asthma\textsuperscript{12}; in a human epithelial cell line\textsuperscript{17}; and in murine vascular smooth muscle cells (VSMCs)\textsuperscript{18}. IL-6 and CXCL8 secretion has also been shown to be attenuated by miRNAs; by \textit{miR}-221 in ASM cells from patients with asthma\textsuperscript{12}; and by \textit{miR}-146\textit{a} and \textit{miR}-146\textit{b} in human alveolar epithelial cells\textsuperscript{19,20}.

Our previous studies have helped to identify \textit{miR}-145 as a potential key regulator of airway smooth muscle function in COPD. Firstly, it is highly expressed in the healthy lung\textsuperscript{21} and in healthy ASM cells specifically\textsuperscript{22}. It has also been shown to be overexpressed in the airways of patients with cystic fibrosis, and to correlate with a decrease in \textit{SMAD3} expression\textsuperscript{23}. A number of human and animal models have linked \textit{miR}-145 to mechanisms that could also contribute towards the development of COPD\textsuperscript{24,25}. Smooth muscle cell proliferation correlated inversely with expression levels of \textit{miR}-145 in murine\textsuperscript{26-28}, leporine\textsuperscript{29} and human\textsuperscript{28} vasculatures. Moreover, exposure to cigarette smoke has been shown to affect expression levels of \textit{miR}-145 in the lungs of rats\textsuperscript{30}. 
We hypothesized that increased IL-6 and CXCL8 release from the ASM cells of COPD patients is mediated by the TGF-β-induced expression of miR-145. We examined the effects of TGF-β upon ASM IL-6 and CXCL8 release from patients with COPD, and in healthy non-smokers and healthy smokers. We then examined the regulation of miR-145 with specific kinase inhibitors. Finally, we examined the effects of modulating the expression levels of miR-145 in these cells on cytokine release and on the phosphorylation of SMAD3. miR-145 controls the excessive cytokine release observed in ASM cells from patients with COPD, by reducing SMAD3 phosphorylation.

Materials & Methods

Primary human ASM cell culture

Primary human ASM cells were previously dissected from the lungs of healthy non-smokers, healthy smokers and patients with COPD; disease and smoking status were defined according to guidelines produced by the American Thoracic Society. Healthy smokers had a smoking history of at least 10 pack years. There were significant differences between FEV₁ in litres, FEV₁ percent predicted, and FEV₁/FVC ratio between smokers and patients with COPD compared with non-smokers but matched for age and smoking history (Table 1).

ASM cells were cultured and plated as previously described. ASM cells were plated onto 96-well plates for the measurement of cytokine release, and six well plates for RNA and protein extraction. Confluent cells were growth-arrested by FCS deprivation for 24 h in Dulbecco’s Modified Eagle’s Medium supplemented with sodium pyruvate (1 mM), L-glutamine (2 mM), nonessential amino acids (1:100), penicillin (100 U/ml)/streptomycin (100 mg/ml), amphotericin B (1.5 mg/ml), and BSA (0.1 %). Passages 3–4 from nine different donors were used. Cells were stimulated in triplicate ± TGF-β at the indicated concentrations.
Alternatively, ASM cells were cultured for 1 h in the presence or absence of the indicated concentrations of TPCA-1 (an IKK-2 inhibitor), PD098059 (a MEK-1/2 inhibitor), SP600125 (a JNK-1/2 inhibitor) and SB 203580 (a p38 MAP kinase inhibitor) and then stimulated with 1 ng/ml of TGF-β for 24 h. All inhibitors were obtained from Calbiochem. The supernatants were removed, and IL-6 and CXCL8 levels were determined by DuoSet ELISA (R&D Systems, Abingdon, UK).

miRNA and mRNA Expression

The human (hsa)-miR-145 and SMAD3 expression levels were measured as previously described. Transfection with miR-145 mimics and controls

ASM cells were transfected as previously described. A mimic for miR-145 and controls were obtained from Ambion/Applied Biosystems, Ltd. (Paisley, UK). Transfected cells were plated into 96-well or 6-well plates, and left to adhere overnight before being serum starved for 6 hours before stimulation with 1 ng/ml TGF-β for the indicated times.

Western Blotting

Proteins were measured as previously described. Antibodies against human phospho-S423-S425-Smad3 and β-actin were purchased from AbCam (Cambridge, UK).

Data Analysis

Data were analysed using GraphPad Prism, version 5.03 (GraphPad Software, San Diego, CA). Data were not normally distributed (as assessed by the Kolmogorov-Smirnov test), and
therefore groups were compared using the Dunn nonparametric test. All data are expressed as means ± SEMs. Significance was defined as a P value of less than 0.05.

Results

The effect of TGF-β stimulation on CXCL8 and IL-6 release and SMAD3 and miR-145 expression by ASM cells after 24 hours

ASM cells were stimulated with 2.5 % FCS and TGF-β at the indicated concentrations (0.001 - 10 ng/ml) for 24 h. TGF-β induced a concentration dependent increase in CXCL8 and IL-6 release from ASM cells which plateaued at 1 ng/ml in the non-smokers (p < 0.05), smokers (p < 0.01) and COPD (p < 0.001) cells (Figure 1A&B). A significant increase in CXCL8 release was observed in the COPD ASM cells compared to the non-smokers (p < 0.01) when the ASM cells were stimulated with 1 ng/ml of TGF-β (Figure 1A), furthermore, there was significant increase in IL-6 release between the non-smokers and smokers (p < 0.01), non-smokers and COPDs (p < 0.001), and the smoker and COPD ASM cells (p < 0.05) (Figure 1B).

TGF-β (0.01 ng/ml) induced an increase in SMAD3 expression in ASM cells from COPD patients ~60-fold higher than baseline (p < 0.001; Figure 1C). Relatively little change to SMAD3 expression was seen in the non-smokers and smokers compared to unstimulated cells. miR-145 expression in ASM cells from COPD patients exhibited a concentration dependent increase which plateaued at 1 ng/ml (p < 0.01) (Figure 1D). A significant increase in expression was observed in the COPD ASM cells compared to the non-smokers and smokers (both p < 0.01) (Figure 1D).

The effects of specific kinase inhibitors on CXCL8 and IL-6 release by ASM cells stimulated with FCS and TGF-β after 24 hours
In previous studies, we and others have demonstrated that cytokines can induce activation of IKK2/NF-κB and the MAP kinases, ERK-1/2, JNK-1/2 and p38 MAP kinase in ASM cells and that these are inhibited in the presence of the selective pharmacological inhibitors of these \textsuperscript{34-43}. We therefore used the biological active concentrations of these inhibitors to examine the role of the NF-κB and MAP kinases pathways during \textit{miR-145} expression.

Following 1 h pre-treatment with inhibitors, ASM cells were stimulated with TGF-β (1 ng/ml) and the generation of IL-6 (\textbf{Figure 2A,D,G&J}), CXCL8 (\textbf{Figure 2B,E,H&K}) and \textit{miR-145} (\textbf{Figure 2C,F,I&L}) were determined at 24 h. Exposure to TPCA-1 completely inhibited production of IL-6 and CXCL8 in the non-smokers at 10 μM, and a significant reduction was observed in the COPD ASM cells (both p <0.05) (\textbf{Figure 2A&B}). No effect was observed upon \textit{miR-145} expression (\textbf{Figure 2C}). The MEK-1/2 inhibitor (10 μM) also attenuated IL-6 and CXCL8 production (both p <0.05) (\textbf{Figure 2D&E}). Interestingly, a significant increase in \textit{miR-145} expression was observed in the COPD ASM cells (p < 0.05) (\textbf{Figure 2F}). Inhibition of the JNK-1/2 kinase demonstrated no effect upon either cytokine release or \textit{miR-145} expression (\textbf{Figure 2G,H&I}). In contrast, inhibition of the p38 MAP kinase had differential actions upon cytokine and \textit{miR-145} production. Blocking p38 MAP kinase inhibited CXCL8 but not IL-6 in both the non-smoker and COPD ASM cells (\textbf{Figure 2J&K}), and a significant increase in \textit{miR-145} expression was observed in the COPD ASM cells (\textbf{Figure 2L}). Overall, pharmacological studies indicate that TGF-β- induced \textit{miR-145} expression is regulated via an MEK-1/2- and p38-dependent pathway.

\textit{The effect upon TGF-β-stimulated ASM cells of \textit{miR-145} overexpression on CXCL8 and IL-6 release}

To clarify the role of \textit{miR-145}, we examined the effect of over-expressing \textit{miR-145} on TGF-β–induced CXCL8 and IL-6 release. Transfection using Amaxa electroporation (Lonza,
Slough, UK) showed that *miR-145* mimics (100 nM) inhibited CXCL8 release by approximately 47% (p < 0.01), and IL-6 release by approximately 49% (p < 0.001), to levels comparably seen in the healthy smokers (*Figure 3A&B*). Altering the endogenous levels of *miR-145* exerted no effect in either healthy or smoker ASM cells or those from patients with severe asthma. To confirm efficient transfection, we undertook parallel studies that examined the effects of a small, interfering RNA (100 nM) targeted to *IL-6*. As demonstrated previously\(^{12,41}\), we showed a reduction in IL-6 release induced by TGF-β stimulation in ASM cells (*Data not shown*), with no effect upon cell viability (*Data not shown*).

**Effects of *miR-145* on SMAD3**

We next determined whether *miR-145* could regulate SMAD3 phosphorylation. As previously demonstrated\(^{33}\), TGF-β (1 ng/ml) increased SMAD3 phosphorylation in the non-smoker ASM cells at 24 h (p < 0.05) (*Figure 3C*). For the first time, we demonstrate that there is a slight increase in phosphorylation in the non-smokers, and an even greater degree of phosphorylation in the ASM cells from COPD patients induced by TGF-β (p < 0.001) (*Figure 3C*). The *miR-145* mimic (100 nM) decreased the TGF-β-induced phosphorylation of SMAD3 in the COPD ASM cells by approximately 50% (p < 0.05) (*Figure 3C*), and demonstrated no effect upon either the non-smoker or smoker ASM cells.
We have made several important observations regarding the behaviour of ASM cells from patients with COPD. First, we showed that TGF-β increased both ASM IL-6 and CXCL8 release in the COPD patients to a greater degree than those from the non-smoker subjects. We also observed a concurrent increase in the expression of both SMAD3 and miR-145 in the ASM cells from the COPD patients. We next investigated the mechanisms that regulate the expression of miR-145. We showed that expression of miR-145 is mediated, at least in part, through activation of MEK-1/2 and p38 in ASM cells from COPD patients. Examination of the effect of these MAP kinase inhibitors upon generation of inflammatory mediators showed that IL-6 release was mediated via IKK2 and MEK-1/2 whilst CXCL8 release was mediated via IKK2, MEK-1/2 and p38 in both the ASM cohorts, from non-smokers and those with COPD. Finally, we found that miR-145 regulates the enhanced IL-6 and CXCL8 release seen in the ASM cells from patients with COPD, that could be partly through the control of SMAD3 (Summarised in Figure 5).

Previous observations have described the effect of inducing hyperproliferation of ASM cells with TGF-β in both asthma\(^ {11;12} \) and COPD\(^ {44} \). This is the first time that TGF-β has been shown to induce both IL-6 and CXCL8 release from primary ASM cells isolated from individuals with COPD. The regulation of smooth muscle cell phenotype has previously been shown to be correlated with expression of miR-145. Specifically, miR-145 has been demonstrated to regulate smooth muscle cell fate\(^ {26;45} \), the contractile phenotype of VSMCs\(^ {27;46} \), and acts a novel VSMC phenotypic marker in murine models\(^ {28} \), and prevent vein graft disease in rabbits\(^ {29} \). Interestingly, exposure to cigarette smoke has been shown to affect expression levels of miR-145 in the lungs of rats\(^ {30} \), and has been found to be differentially expressed in lung homogenates in rats with COPD\(^ {47} \). Furthermore, miR-145 (along with others) has recently been proposed to be a promising plasma based biomarker for the diagnosis of
COPD. This is the first time that a role for miR-145 in the ASM cells from COPD patients has been reported. We have shown that expression of miR-145 is through activation of both MEK-1/2 and p38. Interestingly, Hu et al., have reported that activation of MEK-1/2 suppresses miR-145 expression in VSMCs, and Kent et al., demonstrate that miR-145 expression is inhibited through activation of the MAPK and JNK pathways in colorectal cancer. Furthermore, in cardiomyocytes the protective activity of miR-145 is associated with modulation of both MEK-1/2 and JNK and in gastric mucosal epithelial cell regulation of miR-145 involves JNK. Similarly to our results, p38 has previously been shown to be linked to miR-145 induction in VSMCs and Hong et al., suggest that the p38 MAPK signalling pathway promotes miRNA biogenesis by facilitating the nuclear localization of p68. Clearly, the regulation of miR-145 is, unsurprisingly, cell type specific.

Finally, we examined the effect of increasing miR-145 expression in ASM cells from COPD patients upon IL-6 and CXCL8 release. Although studies have suggested a correlation between miR-145 expression and IL-6 & CXCL8 release, we show for the first time that increasing the expression of miR-145 can reduce levels of IL-6 & CXCL8 release from the COPD ASM cells to levels comparable to that of the non-smoker ASM cells. miR-145 is proposed to target SMAD3 in systemic sclerosis (SSc), cystic fibrosis, cartilage dysfunction, nasopharyngeal cancer and in hypertrophic scar fibroblasts (HSFBs), we show here that this may also be the case in ASM cells from patients with COPD.

Interestingly, miR-145 is also likely to be important in regulating ASM cells in asthma, as it is highly expressed in the healthy lung and in healthy ASM cells specifically, and inhibition of miR-145 inhibits eosinophilic inflammation, mucus hypersecretion, Th2 cytokine production, and airway hyperresponsiveness in house dust mite-induced allergic mouse airways.
In conclusion, miR-145 is vital in controlling the increased inflammatory response of human ASM cells in patients with COPD. This finding may open a new avenue in COPD therapeutics by targeting of miRNA-145 and diagnosis by its detection.
Table 1: Patient Characteristics

|                | Non-Smokers | Smokers | COPD |
|----------------|-------------|---------|------|
| **n**          | 9           | 9       | 9    |
| Age (yrs.)     | 66.4 ± 12.72| 59.2 ± 7.6 | 65.4 ± 6.6 |
| Sex (♂ - ♀)    | 7 – 2       | 4 – 5   | 5 – 5 |
| Pack Years Smoking | N/A       | 29.25 ± 3.3 | 38.32 ± 26.92 |
| FEV₁ (L)       | 4.02 ± 0.48 | 3.12 ± 0.78 | 1.76 ± 0.45 |
| FEV₁ (% Predicted) | 104.23 ± 7.28 | 101.5 ± 4.51 | 77 ± 21.97 |
| FEV₁/FVC (%)   | 78.89 ± 5.98 | 77.57 ± 3.32 | 38.88 ± 15.75 |
| PC₂₀ (mg/ml)   | > 16        | > 16    | Too Severe |

Definition of abbreviations: FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; PC₂₀, provocative concentration of methacholine causing a 20% fall in FEV₁.

Data shown as mean ± SEM.

Figure legends

**Figure 1:** Effect of increasing concentrations of transforming growth factor–β (TGF-β) on airway smooth muscle (ASM) CXCL8 (A) and IL-6 release (B), SMAD3 (C) and miR-145 (D) expression from the ASM cells of non-smokers, smokers and patients with COPD at 24 h. Points represent the means ± SEMs from nine ASM donors in each group. */# p < 0.05; **/## p < 0.01; ***/####/$$$/## p < 0.001. Asterisks indicate comparison with no TGF-β control. Hash signs indicate COPD vs. non-smoker ASM cells. Dollar signs indicate COPD vs. smoker ASM cells. Plus signs indicate smoker vs. non-smoker ASM cells.

**Figure 2:** Effect of inhibitors of IKK2 and MAP kinases upon TGF-β-induced IL-6 and CXCL8 release, and miR-145 expression from the ASM cells of non-smokers and patients with COPD at 24 h. ASM cells were pre-treated for 60 min with the indicated concentrations of the inhibitors of IKK-2 (TPCA-1), MEK-1/2 (PD098059), JNK-1/2 (SP600125) and p38 MAP kinase (SB203580). Following exposure to vehicle control or TGF-β (1 ng/ml) for 24 h the release of IL-6 and CXCL8 was determined by ELISA. miR-145 expression was measured by RT-PCR. Points represent the means ± SEM of nine ASM donors in each group. */# p < 0.05; ** p < 0.01; *** p < 0.001. Asterisks indicate stimulated non-smoker comparison
with no TGF-β control. Hash signs indicate stimulated COPD comparison with no TGF-β control.

**Figure 3:** Effects of the overexpression of miR-145 in the ASM cells of non-smokers, smokers and patients with COPD at 24 h. ASM cells were electroporated in the presence of buffer, control mimic or miR-145 mimic. Cells were then exposed to vehicle control or 1 ng/ml TGF-β and the release of CXCL8 (A) and IL-6 (B) was measured by ELISA at 24 h. Furthermore, p-SMAD3 was measure by Western blotting (C). Points represent the means ± SEMs from nine ASM donors in each group. */# p < 0.05; **/##/++ p < 0.01; ***## p < 0.001.

**Figure 4:** SMAD3 dependent regulation of IL-6 & CXCL8 release by TGF-β-induced miR-145 expression. In response to TGF-β stimulation, MEK-1/2 and p38 activation results in increased miR-145 expression. The concurrent increase in expression and phosphorylation of SMAD3, is regulated by miR-145 to prevent further generation and release of IL-6 & CXCL8.
(1) Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370(9589):741-750.

(2) Vestbo J, Hurd SS, Agusti AG et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347-365.

(3) Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11):e442.

(4) Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35(1):71-86.

(5) Jeffery PK. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004; 1(3):176-183.

(6) Trian T, Benard G, Begueret H et al. Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma. J Exp Med 2007; 204(13):3173-3181.

(7) Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26):2645-2653.

(8) Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077):1645-1648.

(9) Prakash YS. Airway smooth muscle in airway reactivity and remodeling: what have we learned? Am J Physiol Lung Cell Mol Physiol 2013; 305(12):L912-L933.

(10) Bhowmik A, Seemungal TA, Sapsford RJ et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55(2):114-120.

(11) Perry MM, Durham AL, Austin PJ et al. BET bromodomains regulate TGF-beta-induced proliferation and cytokine release in asthmatic airway smooth muscle. J Biol Chem 2015.

(12) Perry MM, Baker JE, Gibeon DS et al. Airway Smooth Muscle Hyperproliferation Is Regulated by MicroRNA-221 in Severe Asthma. Am J Respir Cell Mol Biol 2013; 50(1):7-17.

(13) Takizawa H, Tanaka M, Takami K et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2001; 163(6):1476-1483.

(14) Yeganeh B, Mukherjee S, Moir LM et al. Novel non-canonical TGF-beta signaling networks: emerging roles in airway smooth muscle phenotype and function. Pulm Pharmacol Ther 2013; 26(1):50-63.

(15) Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005; 19(23):2783-2810.
Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009; 136(2):215-233.

Zhang C, Zhang J, Zhang A et al. PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol 2010; 37(6):1621-1626.

Liu X, Cheng Y, Zhang S et al. A Necessary Role of miR-221 and miR-222 in Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia. Circ Res 2009; 104(4):476-487.

Perry MM, Moschos SA, Williams AE et al. Rapid Changes in MicroRNA-146a Expression Negatively Regulate the IL-1beta-Induced Inflammatory Response in Human Lung Alveolar Epithelial Cells. The Journal of Immunology 2008; 180(8):5689-5698.

Perry MM, Williams AE, Tsitsiou E et al. Divergent intracellular pathways regulate interleukin-1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells. FEBS Letters 2009; 583(20):3349-3355.

Williams AE, Larn-Svensson H, Perry MM et al. MicroRNA Expression Profiling in Mild Asthmatic Human Airways and Effect of Corticosteroid Therapy. PLoS ONE 2009; 4(6):e5889.

Perry M, Tsitsiou E, Austin P et al. Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respiratory Research 2014; 15(1):58.

Megiorni F, Cialfi S, Cimino G et al. Elevated levels of miR-145 correlate with SMAD3 down-regulation in cystic fibrosis patients. J Cyst Fibros 2013; 12(6):797-802.

Perry MM, Adcock IM, Chung KF. Role of microRNAs in allergic asthma: present and future. Curr Opin Allergy Clin Immunol 2015; 15(2):156-162.

Brook PO, Perry MM, Adcock IM et al. Epigenome-modifying tools in asthma. Epigenomics 2015; 7(6):1017-1032.

Cordes KR, Sheehy NT, White MP et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460(7256):705-710.

Boettger T, Beetz N, Kostin S et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119(9):2634-2647.

Cheng Y, Liu X, Yang J et al. MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation. Circ Res 2009; 105(2):158-166.

Ohnaka M, Marui A, Yamaha K et al. Effect of microRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype. J Thorac Cardiovasc Surg 2014; 148(2):676-682.

Izzotti A, Calin GA, Arrigo P et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. Faseb J 2009; 23(3):806-812.

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152(S Pt 2):S77-121.
(32) Perry MM, Hui CK, Whiteman M et al. Hydrogen Sulfide Inhibits Proliferation and Release of IL-8 from Human Airway Smooth Muscle Cells. Am J Respir Cell Mol Biol 2011; 45(4):746-752.

(33) Michaeloudes C, Sukkar MB, Khorasani NM et al. TGF-beta regulates Nox4, MnSOD and catalase expression and IL-6 release in airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2010; 300:L295-L304.

(34) Wuyts WA, Vanaudenaerde BM, Dupont LJ et al. Involvement of p38 MAPK, JNK, p42/p44 ERK and NF-kappaB in IL-1beta-induced chemokine release in human airway smooth muscle cells. Respir Med 2003; 97(7):811-817.

(35) Oltmanns U, Issa R, Sukkar MB et al. Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol 2003; 139(6):1228-1234.

(36) Wang CC, Lin WN, Lee CW et al. Involvement of p42/p44 MAPK, p38 MAPK, JNK, and NF-kappaB in IL-1beta-induced VCAM-1 expression in human tracheal smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2005; 288(2):L227-L237.

(37) Laporte JD, Moore PE, Lahiri T et al. p38 MAP kinase regulates IL-1 beta responses in cultured airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 279(5):L932-L941.

(38) Laporte JD, Moore PE, Abraham JH et al. Role of ERK MAP kinases in responses of cultured human airway smooth muscle cells to IL-1beta. Am J Physiol 1999; 277(5 Pt 1):L943-L951.

(39) Hedges JC, Singer CA, Gerthoffer WT. Mitogen-activated protein kinases regulate cytokine gene expression in human airway myocytes. Am J Respir Cell Mol Biol 2000; 23(1):86-94.

(40) Hallsworth MP, Moir LM, Lai D et al. Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle. Am J Respir Crit Care Med 2001; 164(4):688-697.

(41) Larner-Svensson HM, Williams AE, Tsitsiou E et al. Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle. Respir Res 2010; 11:68.

(42) Issa R, Xie S, Lee KY et al. GRO-alpha regulation in airway smooth muscle by IL-1beta and TNF-alpha: role of NF-kappaB and MAP kinases. Am J Physiol Lung Cell Mol Physiol 2006; 291(1):L66-L74.

(43) Shan L, Redhu NS, Saleh A et al. Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. J Immunol 2010; 184(12):7134-7143.

(44) Wiegman CH, Michaeloudes C, Haji G et al. Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2015.

(45) Yamaguchi S, Yamaha K, Homma K et al. The role of microRNA-145 in human embryonic stem cell differentiation into vascular cells. Atherosclerosis 2011; 219(2):468-474.
Hutcheson R, Terry R, Chaplin J et al. MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2013; 33(4):727-736.

Li B, Zhou X, Chen L et al. Expression of microRNAs in lung homogenates in rats with chronic obstructive pulmonary disease. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014; 26(12):905-909.

Wang M, Huang Y, Liang Z et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2016; 10(1):104-111.

Hu B, Song JT, Qu HY et al. Mechanical stretch suppresses microRNA-145 expression by activating extracellular signal-regulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype. PLoS ONE 2014; 9(5):e96338.

Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2013; 32(20):2576-2585.

Li R, Yan G, Zhang Q et al. miR-145 inhibits isoproterenol-induced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6. FEBS Lett 2013; 587(12):1754-1761.

Luo XJ, Liu B, Dai Z et al. Expression of apoptosis-associated microRNAs in ethanol-induced acute gastric mucosal injury via JNK pathway. Alcohol 2013; 47(6):481-493.

Blumensatt M, Wronkowitz N, Wiza C et al. Adipocyte-derived factors impair insulin signaling in differentiated human vascular smooth muscle cells via the upregulation of miR-143. Biochim Biophys Acta 2014; 1842(2):275-283.

Hong S, Noh H, Chen H et al. Signaling by p38 MAPK stimulates nuclear localization of the microprocessor component p68 for processing of selected primary microRNAs. Sci Signal 2013; 6(266):ra16.

Oliva EN, Cuzzola M, Aloe Spiriti MA et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol 2013; 92(1):25-32.

Yu CC, Tsai LL, Wang ML et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013; 73(11):3425-3440.

Li W, Ma K, Zhang S et al. Pulmonary MicroRNA Expression Profiling in an Immature Piglet Model of Cardiopulmonary Bypass-Induced Acute Lung Injury. Artif Organs 2015; 39(4):327-335.

Zhou J, Chaudhry H, Zhong Y et al. Dysregulation in microRNA expression in peripheral blood mononuclear cells of sepsis patients is associated with immunopathology. Cytokine 2015; 71(1):89-100.

Zhu H, Li Y, Qu S et al. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol 2012; 32(3):514-522.

Yang B, Kang X, Xing Y et al. Effect of microRNA-145 on IL-1beta-induced cartilage degradation in human chondrocytes. FEBS Lett 2014; 588(14):2344-2352.
(61) Huang H, Sun P, Lei Z et al. miR-145 inhibits invasion and metastasis by directly targeting Smad3 in nasopharyngeal cancer. Tumour Biol 2015.

(62) Zhu HY, Li C, Zheng Z et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145. Biochem Biophys Res Commun 2015; 459(1):49-53.

(63) Collison A, Mattes J, Plank M et al. Inhibition of house dust mite–induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. Journal of Allergy and Clinical Immunology 2011; 128(1):160-167.